Christian Hourani, MD
Interventional Cardiology · Wichita, KSNPI 1538480538
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 33.1% of the total. Reporting peaked in 2019 at $5,245 and has fallen 82.7% since, to $907 in 2025.
Across 247 payments — averaging $68.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Abiomed$965
- Biotronik Inc.$402
- Boston Scientific$399
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$3,00018%
- Travel & lodging$4,03724%
- Food & beverage$9,93858%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 80 | $5,629 |
| Abbott | 51 | $4,193 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $3,239 |
| Abiomed | 8 | $965 |
| Biotronik Inc. | 3 | $402 |
| Boston Scientific | 8 | $399 |
| AstraZeneca | 23 | $360 |
| Inari Medical, Inc. | 2 | $306 |
| Amgen | 14 | $199 |
| Edwards Lifesciences | 1 | $166 |
| Novartis | 9 | $160 |
| Boehringer Ingelheim | 2 | $137 |
| Merck | 3 | $122 |
| Johnson & Johnson | 2 | $118 |
| Penumbra, Inc. | 1 | $111 |
| Gilead | 5 | $77 |
| Pfizer | 5 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $51 |
| Novo Nordisk | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $36 |
| Cvrx, Inc. | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Shockwave Medical, Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$3,000
- Advisa$2,092
- Omnilink Elite vascular stent system$1,516
- Micra$987
- FLOWTRIEVER CATHETER, S$612
- Impella$569
- ReCross$260
- PK Papyrus$260
- TrapIT$260
- Pantera LEO$260
- Orsiro Mission$260
- Xience V coronary stent system$245
- Watchman$231
- Edwards SAPIEN 3 Transcatheter Heart Valve$166
- ASSURITY$156
- MitraClip System$146
- AVEIR$140
- OPTIS$139
- Xience Sierra Coronary Stent System$138
- Resolute$136
How this compares
$17,002 in reported general payments places this provider in the 65th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 475 | $454,327 |
| XareltoRivaroxaban | 403 | $332,196 |
| EntrestoSacubitril/Valsartan | 191 | $186,424 |
| Repatha SureclickEvolocumab | 121 | $150,204 |
| JardianceEmpagliflozin | 52 | $53,345 |
| Praluent PenAlirocumab | 23 | $23,785 |
| FarxigaDapagliflozin Propanediol | 33 | $23,016 |
| Atorvastatin Calcium | 1,453 | $9,953 |
| Ranolazine ErRanolazine | 109 | $9,635 |
| Metoprolol Succinate | 782 | $7,472 |
| Ezetimibe | 240 | $6,449 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 261 | $5,888 |
| Prasugrel Hcl | 75 | $5,484 |
| Potassium Chloride | 319 | $4,848 |
| Flecainide Acetate | 131 | $4,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $454,327475 claims |
| Johnson & JohnsonXarelto | $118 | $332,196403 claims |
| NovartisEntresto | $160 | $186,424191 claims |
| Boehringer IngelheimJardiance | $137 | $53,34552 claims |
| AstraZenecaFarxiga | $360 | $23,01633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Wichita
- Maheedhar GedelaWichita$54K
- Hussam FarhoudWichita$25K
- Gaurav TyagiWichita$13K
- Ravi BajajWichita$10K
- Assem FarhatWichita$9K
- Venkata BoppanaWichita$9K
- Alaa BouladWichita$8K
- Rohma ShaikhWichita$4K
- George ReaderWichita$4K
- Mohamed ElmassryWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.